Skip to main content
Top
Published in: International Journal of Hematology 2/2019

01-02-2019 | Case Report

Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia

Authors: Kaito Harada, Noritaka Sekiya, Shuntaro Ikegawa, Shugo Sasaki, Takeshi Kobayashi, Kazuteru Ohashi

Published in: International Journal of Hematology | Issue 2/2019

Login to get access

Abstract

Cytomegalovirus meningitis/meningoencephalitis is a potentially fatal complication following hematopoietic stem cell transplantation that causes significant morbidity and mortality. In the pre-transplant setting, a few cases involving lymphoid malignancies have been reported. However, there have been no reports of patients with myeloid malignancies. A 36-year-old man with relapsed acute myeloid leukemia received high-dose cytarabine-containing salvage chemotherapies and then developed grade 4 lymphopenia for more than one month. Subsequently, the patient developed pyrexia, accompanying headache, nausea, and vomiting with no abnormal brain imaging. Despite receiving antimicrobial treatment, his febrile status and headache persisted. Given that the patient had symptoms consistent with viral meningitis with no evidence of etiology other than positive cytomegalovirus-DNA in his cerebrospinal fluid and cytomegalovirus pp65 antigenemia, cytomegalovirus meningitis was diagnosed. After commencing ganciclovir treatment, the patient’s headache and febrile status rapidly improved. Cytomegalovirus meningitis/meningoencephalitis is rare before hematopoietic stem cell transplantation, but may be useful in differential diagnoses in heavily treated acute myeloid leukemia patients with central nervous system symptoms.
Literature
1.
go back to reference Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91.CrossRefPubMed Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91.CrossRefPubMed
2.
go back to reference Cinque P, Cleator GM, Weber T, Monteyne P, Sindic C, Gerna G, et al. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. European Union Concerted Action on Virus Meningitis and Encephalitis. J Neurovirol. 1998;4:120–32.CrossRefPubMed Cinque P, Cleator GM, Weber T, Monteyne P, Sindic C, Gerna G, et al. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. European Union Concerted Action on Virus Meningitis and Encephalitis. J Neurovirol. 1998;4:120–32.CrossRefPubMed
3.
go back to reference Matsukawa T, Goto H, Takahashi K, Asanuma S, Yasumoto A, Takahata M, et al. A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations. Int J Hematol. 2012;95:217–22.CrossRefPubMed Matsukawa T, Goto H, Takahashi K, Asanuma S, Yasumoto A, Takahata M, et al. A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations. Int J Hematol. 2012;95:217–22.CrossRefPubMed
4.
go back to reference Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant. 2010;45:979–84.CrossRefPubMed Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant. 2010;45:979–84.CrossRefPubMed
5.
go back to reference Mori T, Kato J. Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int J Hematol. 2010;91:588–95.CrossRefPubMed Mori T, Kato J. Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int J Hematol. 2010;91:588–95.CrossRefPubMed
6.
go back to reference Mussini C, Mongiardo N, Manicardi G, Trenti F, Alessandrì A, Paolillo F, et al. Relevance of clinical and laboratory findings in the diagnosis of cytomegalovirus encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis. 1997;16:437–44.CrossRefPubMed Mussini C, Mongiardo N, Manicardi G, Trenti F, Alessandrì A, Paolillo F, et al. Relevance of clinical and laboratory findings in the diagnosis of cytomegalovirus encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis. 1997;16:437–44.CrossRefPubMed
7.
go back to reference Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 2001;97:3380–9.CrossRefPubMed Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 2001;97:3380–9.CrossRefPubMed
8.
go back to reference Suzumiya J, Marutsuka K, Ueda S, Uno H, Eizuru Y, Sumiyoshi A. An autopsy case of necrotizing ventriculo-encephalitis caused by cytomegalovirus in Hodgkin’s disease. Acta Pathol Jpn. 1991;41:291–8.PubMed Suzumiya J, Marutsuka K, Ueda S, Uno H, Eizuru Y, Sumiyoshi A. An autopsy case of necrotizing ventriculo-encephalitis caused by cytomegalovirus in Hodgkin’s disease. Acta Pathol Jpn. 1991;41:291–8.PubMed
9.
go back to reference Nagayama M, Shinohara Y, Sekiyama S, Takahashi W, Takagi S, Yamamoto M, et al. Intravascular malignant lymphomatosis manifesting clinically as bilateral sudden hearing loss and cytomegalovirus encephalitis. Neurology. 1994;44:1518–20.CrossRefPubMed Nagayama M, Shinohara Y, Sekiyama S, Takahashi W, Takagi S, Yamamoto M, et al. Intravascular malignant lymphomatosis manifesting clinically as bilateral sudden hearing loss and cytomegalovirus encephalitis. Neurology. 1994;44:1518–20.CrossRefPubMed
10.
go back to reference Van DJ, De Ceuninck M, Snoeck HW, Schroyens W, Berneman Z. Successful treatment of cytomegalovirus encephalitis in a patient with Hodgkin’s disease in remission. Ann Hematol. 1998;76:179–81.CrossRef Van DJ, De Ceuninck M, Snoeck HW, Schroyens W, Berneman Z. Successful treatment of cytomegalovirus encephalitis in a patient with Hodgkin’s disease in remission. Ann Hematol. 1998;76:179–81.CrossRef
11.
go back to reference Vallet S, Tempescul A, Tran A, Legrand-Quillien MC, Narbonne V, Berthou C. Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab. Ann Hematol. 2005;84:545–7.CrossRefPubMed Vallet S, Tempescul A, Tran A, Legrand-Quillien MC, Narbonne V, Berthou C. Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab. Ann Hematol. 2005;84:545–7.CrossRefPubMed
12.
go back to reference Suzuki HI, Hangaishi A, Hosoya N, Watanabe T, Kanda Y, Motokura T, et al. Herpes simplex encephalitis and subsequent cytomegalovirus encephalitis after chemoradiotherapy for central nervous system lymphoma: a case report and literature review. Int J Hematol. 2008;87:538–41.CrossRefPubMed Suzuki HI, Hangaishi A, Hosoya N, Watanabe T, Kanda Y, Motokura T, et al. Herpes simplex encephalitis and subsequent cytomegalovirus encephalitis after chemoradiotherapy for central nervous system lymphoma: a case report and literature review. Int J Hematol. 2008;87:538–41.CrossRefPubMed
13.
go back to reference Siakantaris MP, Argyropoulos KV, Ioannou S, Papadopoulou V, Tzeletas G, Tsonis J, et al. Cytomegalovirus meningoencephalitis after rituximab treatment for primary central nervous system lymphoma. Neurologist. 2015;19:35–7.CrossRefPubMed Siakantaris MP, Argyropoulos KV, Ioannou S, Papadopoulou V, Tzeletas G, Tsonis J, et al. Cytomegalovirus meningoencephalitis after rituximab treatment for primary central nervous system lymphoma. Neurologist. 2015;19:35–7.CrossRefPubMed
14.
go back to reference Visani G, Petti MC, Cenacchi A, Manfroi S, Tosi P, Spadea A, et al. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia. Leuk Lymphoma. 1995;19:447–51.CrossRefPubMed Visani G, Petti MC, Cenacchi A, Manfroi S, Tosi P, Spadea A, et al. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia. Leuk Lymphoma. 1995;19:447–51.CrossRefPubMed
15.
go back to reference Hiddemann W, Büchner T, Essink M, Koch O, Stenzinger W, van de Loo J. High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (s-HAM) indicating a high antileukemic activity in refractory acute leukemias. Onkologie. 1988;11:10–2.PubMed Hiddemann W, Büchner T, Essink M, Koch O, Stenzinger W, van de Loo J. High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (s-HAM) indicating a high antileukemic activity in refractory acute leukemias. Onkologie. 1988;11:10–2.PubMed
16.
go back to reference Miyawaki S, Kawai Y, Takeshita A, Komatsu N, Usui N, Arai Y, et al. Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol. 2007;86:343–7.CrossRefPubMed Miyawaki S, Kawai Y, Takeshita A, Komatsu N, Usui N, Arai Y, et al. Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol. 2007;86:343–7.CrossRefPubMed
18.
go back to reference Burke DG, Leonard DG, Imperiale TF, Valdez H, Karaman B, Shick E, et al. The utility of clinical and radiographic features in the diagnosis of cytomegalovirus central nervous system disease in AIDS patients. Mol Diagn. 1999;4:37–43.CrossRefPubMed Burke DG, Leonard DG, Imperiale TF, Valdez H, Karaman B, Shick E, et al. The utility of clinical and radiographic features in the diagnosis of cytomegalovirus central nervous system disease in AIDS patients. Mol Diagn. 1999;4:37–43.CrossRefPubMed
19.
go back to reference Cinque P, Vago L, Brytting M, Castagna A, Accordini A, Sundqvist VA, et al. Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis. 1992;166:1408–11.CrossRefPubMed Cinque P, Vago L, Brytting M, Castagna A, Accordini A, Sundqvist VA, et al. Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis. 1992;166:1408–11.CrossRefPubMed
20.
go back to reference Cinque P, Vago L, Dahl H, Brytting M, Terreni MR, Fornara C, et al. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS. 1996;10:951–8.CrossRefPubMed Cinque P, Vago L, Dahl H, Brytting M, Terreni MR, Fornara C, et al. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS. 1996;10:951–8.CrossRefPubMed
21.
go back to reference Bhaskaran A, Racsa L, Gander R, Southern P, Cavuoti D, Alatoom A. Interpretation of positive molecular tests of common viruses in the cerebrospinal fluid. Diagn Microbiol Infect Dis. 2013;77:236–40.CrossRefPubMed Bhaskaran A, Racsa L, Gander R, Southern P, Cavuoti D, Alatoom A. Interpretation of positive molecular tests of common viruses in the cerebrospinal fluid. Diagn Microbiol Infect Dis. 2013;77:236–40.CrossRefPubMed
22.
go back to reference Ersvaer E, Brenner AK, Vetås K, Reikvam H, Bruserud Ø. Effects of cytarabine on activation of human T cells—cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. BMC Pharmacol Toxicol. 2015;16:12.CrossRefPubMedPubMedCentral Ersvaer E, Brenner AK, Vetås K, Reikvam H, Bruserud Ø. Effects of cytarabine on activation of human T cells—cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. BMC Pharmacol Toxicol. 2015;16:12.CrossRefPubMedPubMedCentral
23.
go back to reference Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol. 2002;49(Suppl 1):13–20.CrossRef Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol. 2002;49(Suppl 1):13–20.CrossRef
25.
go back to reference Goerig NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA, et al. Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain. Neuro Oncol. 2016;18:1664–72.CrossRefPubMedPubMedCentral Goerig NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA, et al. Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain. Neuro Oncol. 2016;18:1664–72.CrossRefPubMedPubMedCentral
26.
go back to reference Zhou K, Boström M, Ek CJ, Li T, Xie C, Xu Y, et al. Radiation induces progenitor cell death, microglia activation, and blood–brain barrier damage in the juvenile rat cerebellum. Sci Rep. 2017;7:46181.CrossRefPubMedPubMedCentral Zhou K, Boström M, Ek CJ, Li T, Xie C, Xu Y, et al. Radiation induces progenitor cell death, microglia activation, and blood–brain barrier damage in the juvenile rat cerebellum. Sci Rep. 2017;7:46181.CrossRefPubMedPubMedCentral
Metadata
Title
Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia
Authors
Kaito Harada
Noritaka Sekiya
Shuntaro Ikegawa
Shugo Sasaki
Takeshi Kobayashi
Kazuteru Ohashi
Publication date
01-02-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2544-x

Other articles of this Issue 2/2019

International Journal of Hematology 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine